Computed Tomography Images under the Nomogram Mathematical Prediction Model in the Treatment of Cerebral Infarction Complicated with Nonvalvular Atrial Fibrillation and the Impacts of Virus Infection
Table 3
Comparison of clinical characteristics between patients in the RVI group and NRVI group after atrial fibrillation.
Variable
Patients in the RVI group (n = 52)
Patients in the NRVI group (n = 248)
P
Diabetes (%)
11 (21.15)
48 (19.35)
0.287
Hyperlipidemia (%)
7 (13.46)
26 (10.48)
0.072
Diuretics (%)
6 (11.54)
21 (8.47)
0.154
Beta blockers (%)
7 (13.46)
27 (10.89)
0.132
Lipid-lowering drugs (%)
23 (44.23)
68 (27.42)
0.045
COPD (%)
2 (0.038)
13 (0.052)
0.218
Antiplatelet drugs (%)
19 (36.54)
72 (0.29)
0.467
Active atrial electrode (%)
28 (53.85)
145 (58.47)
0.523
Active ventricular electrode (%)
38 (73.08)
208 (83.87)
0.765
Cardiac ultrasound
LVEF (%)
5 (9.62)
8 (3.23)
0.231
LAD (%)
21 (40.38)
61 (24.90)
0.056
Laboratory indicators
BUN (mg/L)
5.26 (±1.86)
5.89 (±2.12)
0.248
C-reactive protein (mg/L)
1.5 (0.5–3.9)
1.5 (0.5–4.2)
0.543
Follow-up parameters
AP-VP ≥ 50 (%)
11 (21.15)
19 (7.66)
0.012
AP ≥ 50 (%)
28 (53.84)
82 (33.06)
0.038
VP ≥ 50 (%)
29 (55.77)
89 (35.89)
0.069
Note: COPD refers to chronic obstructive pulmonary disease; LEVF refers to left ventricular ejection fraction; BUN represents blood urea nitrogen; VP refers to the score of sepsis-related organ failure assessment; and AP is the short form of adapted physical activity and cardiac coherence in hematologic patients (APACCHE).
